BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 1315748)

  • 1. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
    J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.
    Conese M; Nykjaer A; Petersen CM; Cremona O; Pardi R; Andreasen PA; Gliemann J; Christensen EI; Blasi F
    J Cell Biol; 1995 Dec; 131(6 Pt 1):1609-22. PubMed ID: 8522616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
    Nykjaer A; Petersen CM; Møller B; Jensen PH; Moestrup SK; Holtet TL; Etzerodt M; Thøgersen HC; Munch M; Andreasen PA
    J Biol Chem; 1992 Jul; 267(21):14543-6. PubMed ID: 1378833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes.
    Nykjaer A; Conese M; Christensen EI; Olson D; Cremona O; Gliemann J; Blasi F
    EMBO J; 1997 May; 16(10):2610-20. PubMed ID: 9184208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor.
    Conese M; Olson D; Blasi F
    J Biol Chem; 1994 Jul; 269(27):17886-92. PubMed ID: 8027043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.
    Cubellis MV; Wun TC; Blasi F
    EMBO J; 1990 Apr; 9(4):1079-85. PubMed ID: 2157592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
    Conese M; Blasi F
    Biol Chem Hoppe Seyler; 1995 Mar; 376(3):143-55. PubMed ID: 7612191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
    Li H; Kuo A; Kochan J; Strickland D; Kariko K; Barnathan ES; Cines DB
    J Biol Chem; 1994 Mar; 269(11):8153-8. PubMed ID: 7510679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.
    Bonavaud S; Charrière-Bertrand C; Rey C; Leibovitch MP; Pedersen N; Frisdal E; Planus E; Blasi F; Gherardi R; Barlovatz-Meimon G
    J Cell Sci; 1997 May; 110 ( Pt 9)():1083-9. PubMed ID: 9175704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
    Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
    J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
    Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
    Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface.
    Ragno P; Montuori N; Rossi G
    Eur J Biochem; 1995 Oct; 233(2):514-9. PubMed ID: 7588796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
    Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
    Czekay RP; Loskutoff DJ
    J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
    Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.